Evidence map›Paper›PMID 37993772›Full record

ArticleBMC geriatrics2023

Plasma acylcarnitine in elderly Taiwanese: as biomarkers of possible sarcopenia and sarcopenia.

Chi-Jen Lo, Chih-Ming Lin, Chun-Ming Fan, Hsiang-Yu Tang, Han-Fang Liu, Hung-Yao Ho, Mei-Ling Cheng

Open access · goldAbstract read
In one paragraph

Article in BMC geriatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chi-Jen Lo *Metabolomics Core Laboratory, Healthy Aging Research Center, Chang Gung University, Taoyuan City, 33302, Taiwan.
Chih-Ming Lin *Division of Internal Medicine, Chang Gung Memorial Hospital, Taipei, 105, Taiwan.
Chun-Ming FanMetabolomics Core Laboratory, Healthy Aging Research Center, Chang Gung University, Taoyuan City, 33302, Taiwan.
Hsiang-Yu TangMetabolomics Core Laboratory, Healthy Aging Research Center, Chang Gung University, Taoyuan City, 33302, Taiwan.
Han-Fang LiuMetabolomics Core Laboratory, Healthy Aging Research Center, Chang Gung University, Taoyuan City, 33302, Taiwan.
Hung-Yao HoMetabolomics Core Laboratory, Healthy Aging Research Center, Chang Gung University, Taoyuan City, 33302, Taiwan.
Mei-Ling ChengMetabolomics Core Laboratory, Healthy Aging Research Center, Chang Gung University, Taoyuan City, 33302, Taiwan. chengm@mail.cgu.edu.tw.
Chang Gung University · TWChang Gung Memorial Hospital · TW

Funding

Chang Gung Memorial Hospital BMRP819, BMRP564, CMRPD1H0201, CMRPD1H0202, CMRPD1J0341, CMRPD1H0511, CMRPD1J0261, CMRPD1M0341Ministry of Education in Taiwan EMRPD1G0251, EMRPD1H0401, EMRPD1I0501, EMRPD1I0461, EMRPD1M0421Ministry of Science and Technology in Taiwan 111-2320-B-182-011
6 · The paper itself

Abstract

backgroundSarcopenia is defined as the disease of muscle loss and dysfunction. The prevalence of sarcopenia is strongly age-dependent. It could bring about disability, hospitalization, and mortality. The purpose of this study was to identify plasma metabolites associated with possible sarcopenia and muscle function to improve disease monitoring and understand the mechanism of muscle strength and function decline.

methodsThe participants were a group of healthy older adult who live in retirement homes in Asia (Taiwan) and can manage their daily lives without assistance. The participants were enrolled and divided into four groups: control (Con, n = 57); low physical function (LPF, n = 104); sarcopenia (S, n = 63); and severe sarcopenia (SS, n = 65) according to Asian countries that used Asian Working Group for Sarcopenia (AWGS) criteria. The plasma metabolites were used and the results were calculated as the difference between the control and other groups.

resultsClinical parameters, age, gender, body mass index (BMI), hand grip strength (HGS), gait speed (GS), blood urea nitrogen (BUN), hemoglobin, and hematocrit were significantly different between the control and LPF groups. Metabolite patterns of LPF, S, and SS were explored in our study. Plasma kynurenine (KYN) and acylcarnitines (C0, C4, C6, and C18:1-OH) were identified with higher concentrations in older Taiwanese adults with possible sarcopenia and S compared to the Con group. After multivariable adjustment, the data indicate that age, BMI, and butyrylcarnitine (C4) are more important factors to identify individuals with low physical function and sarcopenia.

conclusionThis metabolomic study raises the importance of acylcarnitines on muscle mass and function. It suggests that age, BMI, BUN, KYN, and C4/Cr can be important evaluation markers for LPF (AUC: 0.766), S (AUC: 0.787), and SS (AUC: 0.919).

Indexed as

SarcopeniaAgedBiomarkersCarnitineHand StrengthHumansMuscle, SkeletalMuscle StrengthacylcarnitineBiomarkersCarnitineCarnitineMetabolismMuscle massSarcopenia

Identifiers

PMID37993772
PMCPMC10666394
OpenAlexW4388901970

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.